Diabetes mellitus (DM) is a metabolic disease characterized by the onset of hyperglycemia due to secretion disorders, as well as resistance of insulin. Chronic hyperglycemic and other DM metabolic disorders will cause tissue and organ damage, such as the eyes, kidneys and vascular system. Some studies show that immunax (MBJH: minyak biji jinten hitam) has antidibetic benefits. This study aims to determine the description of urinalysis and proteinuria in DM patients who get immunax. The study design was randomized controlled trial. MBJH is given in 2 dosage levels, 2x1 soft capsule and 2x2 soft capsul given for 20 days on the subject. Urine data taken before and after administration of immunax preparations. The results showed that based on sex, age, education, occupation, marital status and the type of therapy used there was no significant difference in the characteristics and types of therapy used by the study subjects (patients at risk of metabolic syndrome) between the treatment groups and the placebo group. The result of urinalysis test showed that there was no difference of urinalysis image in the three groups. The conclusion of this study was that there was no significant effect (p value> 0,05) on immunax (MBJH) on the urinalysis profile in patients with metabolic syndrome risk, both dose 2x1, 2x2, and control group